ONO-4538 + Ipilimumab + Oxaliplatin + Capecitabine + S-1
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer
Trial Timeline
Nov 5, 2021 → May 1, 2027
NCT ID
NCT05144854About ONO-4538 + Ipilimumab + Oxaliplatin + Capecitabine + S-1
ONO-4538 + Ipilimumab + Oxaliplatin + Capecitabine + S-1 is a phase 3 stage product being developed by Ono Pharmaceutical for Gastric Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05144854. Target conditions include Gastric Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05144854 | Phase 3 | Active |
Competing Products
20 competing products in Gastric Cancer